Management of Shortness of Breath and Tachycardia in Lung Carcinoma Patients

Assessment and Causes of Symptoms

Shortness of breath and tachycardia in lung cancer patients can result from multiple causes including the tumor itself, treatment-related toxicity, comorbidities, or complications like pulmonary embolism, as noted by the American College of Chest Physicians and the European Society for Medical Oncology 1, 2
Cough and dyspnea are common symptoms in lung cancer, affecting up to 57% of patients and significantly impacting quality of life, according to the American Thoracic Society and the European Respiratory Society 3, 4
Tachycardia may be related to direct tumor effects, treatment toxicity, hypoxia, pain, emotional stress, or paraneoplastic conditions, as reported by the American College of Cardiology 5, 6

The American College of Chest Physicians recommends determining if symptoms are related to the tumor itself, treatment effects, or complications, and considering bronchoscopy to identify any central airway obstruction that may require specific interventions 1, 2
For shortness of breath, the European Society for Medical Oncology suggests considering endobronchial management options such as argon plasma coagulation, Nd:YAG laser, or electrocautery for central airway lesions, and external beam radiation therapy for distal or parenchymal lesions 1, 2
The American College of Cardiology recommends identifying and correcting any underlying causes of tachycardia, such as hypoxia, pain, or electrolyte abnormalities, and considering beta-blockers with lower potential for drug interactions if symptomatic and hemodynamically stable 5, 6
The European Heart Journal advises avoiding medications that could worsen tachyarrhythmias, such as theophylline, which can potentially worsen tachycardia 7, 8

The American Thoracic Society suggests using opioid derivatives titrated to an acceptable side-effect profile for symptomatic management of dyspnea 4, 9
The European Respiratory Society recommends considering physical exercise programs to improve symptoms of dyspnea and quality of life in lung cancer patients 2
For cough management, the American College of Chest Physicians suggests an initial trial with demulcents, progressing to opioid derivatives if ineffective, and considering peripherally-acting antitussives for opioid-resistant cough 4, 9